Gaudium IVF

Why is Gaudium IVF and Women Health Ltd falling/rising?

As of 10-Aug, Gaudium IVF and Women Health Ltd's stock price is declining, currently at 128.40, with a 1.98% drop and decreased investor participation. Institutional stakes have also fallen, reflecting a loss of confidence, despite the company being net-debt free and having shown long-term growth.

As of 10-Aug, Gaudium IVF and Women Health Ltd's stock price is falling, currently at 128.40, reflecting a decrease of 2.6 or 1.98%. The stock has underperformed its sector by 1.81% today and has experienced consecutive declines over the past two days, resulting in a total drop of 3.09% during this period. <BR><BR>Investor participation has notably decreased, with delivery volume on 07 Aug plummeting by 95.76% compared to the 5-day average, indicating a lack of interest among investors. Additionally, institutional investors have reduced their stakes by 4.08% in the previous quarter, now holding only 5.24% of the company, which suggests a loss of confidence from more knowledgeable market participants.<BR><BR>While the company is net-debt free and has shown healthy long-term growth in net sales, the recent flat results reported on Mar 26 and a high valuation, indicated by a 5.7 enterprise value to capital employed ratio, contribute to the negative sentiment surrounding the stock. Overall, these factors combine to explain the current decline in Gaudium IVF and Women Health Ltd's stock price.

Which are the latest news on Gaudium IVF?

Should I buy, sell or hold Gaudium IVF and Women Health Ltd?

What does Gaudium IVF do?

Gaudium IVF and Women Health Ltd is a micro-cap healthcare services company specializing in IVF treatments, with recent net sales of 30 Cr and a net profit of 8 Cr as of March 2026. Key financial metrics include a P/E ratio of 27.00 and a market cap of INR 766 Cr.

Overview: <BR>Gaudium IVF and Women Health Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not provided. The latest quarterly results reported are for March 2026, showing net sales and profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 30 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 8 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 766 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 27.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.10 <BR>Return on Equity: 16.08% <BR>Price to Book: 5.03 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Gaudium IVF?

As of 10th June, Gaudium IVF and Women Health Ltd has a market capitalization of 766.00 Cr, with recent net sales of 113.51 Cr and a net profit of 27.83 Cr. The balance sheet for March 2025 shows shareholder's funds of 46.30 Cr and total assets of 88.51 Cr.

As of 10th June, Gaudium IVF and Women Health Ltd has a market capitalization of 766.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Gaudium IVF reported Net Sales of 113.51 Cr and a Net Profit of 27.83 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 46.30 Cr and Total Assets of 88.51 Cr.

Who are the peers of the Gaudium IVF?

Gaudium IVF's peers include Tarsons Products, One Global Serv, 3B Blackbio, Health X Platfor, Hemant Surgical, Prevest Denpro, Take Solutions, and Nureca. Hemant Surgical has the highest 1-year return at 278.57%, while Tarsons Products has the lowest at -45.32%.

Peers: The peers of Gaudium IVF are Tarsons Products, One Global Serv, 3B Blackbio, Health X Platfor, Hemant Surgical, Prevest Denpro, Take Solutions, and Nureca.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prevest Denpro, while Average management risk is found at One Global Serv, 3B Blackbio, and Hemant Surgical, and the rest. Below Average management risk is present in Tarsons Products, Health X Platfor, Take Solutions, and Nureca. For Growth, Excellent growth is noted at One Global Serv, Good growth at Hemant Surgical, and the rest show Below Average or Average growth. In terms of Capital Structure, Excellent capital structure is seen in One Global Serv, 3B Blackbio, Health X Platfor, and Prevest Denpro, while Good capital structure is noted at Tarsons Products and Hemant Surgical, and Below Average capital structure is present in Take Solutions and Nureca.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Hemant Surgical at 278.57%, while the lowest is Tarsons Products at -45.32%. Gaudium IVF's 1-year return is not available for comparison. Additionally, several peers, including Take Solutions, Nureca, Prevest Denpro, and others, have negative six-month returns.